{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:18:12Z","timestamp":1782278292473,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1502,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41379-018-0097-4","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T11:39:52Z","timestamp":1530704392000},"page":"1801-1806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Expression of PD-L1\/PD-1 in lymphoepithelioma-like carcinoma of the thymus"],"prefix":"10.1016","volume":"31","author":[{"given":"David","family":"Suster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Pihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Mackinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Suster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0097-4_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2559.2004.01796.x","article-title":"Thymic carcinoma: a clinicopathological and immunohistological study of 19 cases","volume":"44","author":"Chalabreysse","year":"2004","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0097-4_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00428-013-1371-y","article-title":"Thymic carcinomas: clinicopathologic study of 37 cases from a single institution","volume":"462","author":"Thomas de Montpr\u00e9ville","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1038\/s41379-018-0097-4_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1309\/AJCP88FZTWANLRCB","article-title":"Thymic carcinoma, part 1: a clinicopathologic and immunohistochemical study of 65 cases","volume":"138","author":"Weissferdt","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-018-0097-4_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","article-title":"Thymic carcinoma: a clinicopathologic study of 60 cases","volume":"67","author":"Suster","year":"1991","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib7","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.21037\/jtd.2016.08.82","article-title":"Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors","volume":"8","author":"Leisibach","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1038\/s41379-018-0097-4_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1038\/s41379-018-0097-4_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11864-017-0495-8","article-title":"Novel agents in the treatment of thymic malignancies","volume":"18","author":"Merveilleux du Vignaux","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"10.1038\/s41379-018-0097-4_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0097-4_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0097-4_bib13","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0097-4_bib14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1038\/s41379-018-0097-4_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.21037\/atm.2017.06.11","article-title":"Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy","volume":"5","author":"Zuazo","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1038\/s41379-018-0097-4_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1038\/s41379-018-0097-4_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bulcan.2017.10.030","article-title":"Atezolizumab (Tecentriq\u00ae): activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma","volume":"105","author":"Bernard-Tessier","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1038\/s41379-018-0097-4_bib19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0097-4_bib20","unstructured":"Suster D, Mackinnon AC, Pihan G, et al. Poorly-differentiated non-keratinizing squamous cell thymic carcinoma: a clinicopathologic, immunohistochemical and molecular genetic study of 25 cases. Mod Pathol 2017;30(S2): 496A."},{"key":"10.1038\/s41379-018-0097-4_bib21","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0097-4_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2016.01.004","article-title":"Medical treatment involving investigational drugs and genetic profile of thymic carcinoma","volume":"93","author":"Asao","year":"2016","journal-title":"Lung Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0097-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222011346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222011346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:44:30Z","timestamp":1760229870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222011346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0893395222011346"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0097-4","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of PD-L1\/PD-1 in lymphoepithelioma-like carcinoma of the thymus","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0097-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}